Last reviewed · How we verify
Thiamine 2
Thiamine 2, developed by Mahidol University, is a marketed drug with a key composition patent expiring in 2028. The drug's market position and primary indication are not specified, but the patent protection provides a competitive advantage until 2028. The primary risk is the potential increase in competition post-patent expiry in 2028.
At a glance
| Generic name | Thiamine 2 |
|---|---|
| Sponsor | Mahidol University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers (PHASE1)
- Synbiotic Supplement With Botanical Extracts for Gut Microbiota Balance in Irritable Bowel Syndrome (NA)
- Type 2 Diabetes and Blood Brain Barrier Improvement (EARLY_PHASE1)
- Assessing the Impact of Herbal Supplement on Fatigue and Disease Activity in SLE: Results From an 8-Week Randomized Trial (NA)
- The Critical Link Between Gut Microbiome Dysfunction, Cravings and Relapse: RECLAIM-GUT TRIAL (NA)
- A Study to See Whether Taking a Mix of Vitamins Can Help Adults Recover Better After Surgery for Carpal Tunnel Syndrome (NA)
- Evaluation of an ATP-Containing Parenteral Vitamin B Complex in Patients With Symptomatic Diabetic Polyneuropathy (PHASE4)
- Human Albumin for Resuscitation in Surgical Septic Shock: A Randomized Controlled Trial (ALBUS Study) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thiamine 2 CI brief — competitive landscape report
- Thiamine 2 updates RSS · CI watch RSS
- Mahidol University portfolio CI